Perillyl Alcohol Promotes Relaxation in Human Umbilical Artery

Overview

Journal Curr Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2024 Jan 11

PMID 38204229

Authors

Carla Mikevely de Sena Bastos

Luis Pereira-de-Morais

Andressa de Alencar Silva

Debora de Menezes Dantas

Paulo Ricardo Batista

Maria Franciele Lima Gomes

Gyllyandeson de Araujo Delmondes

Irwin Rose Alencar de Menezes

Renata Evaristo Rodrigues da Silva

Roseli Barbosa

Affiliations

Soon will be listed here.

Abstract

Background: Perillyl alcohol (POH) is a monoterpenoid found in plant essential oils and has been shown to relax murine vessels, but its effect on human vessels remains poorly studied.

Objective: The study aimed to characterize the effect of POH on human umbilical arteries (HUA).

Methods: Rings of HUA were obtained from uncomplicated patients and suspended in an organ bath for isometric recording. The vasorelaxant effect of POH in HUA was evaluated on basal tone and electromechanical or pharmacomechanical contractions, and possible mechanisms of action were also investigated.

Results: POH (1-1000 μM) altered the basal tone of HUA and completely relaxed HUA rings precontracted with KCl (60 mM) or 5-HT (10 μM), obtaining greater potency in the pharmacomechanical pathway (EC 110.1 μM), suggesting a complex interference in the mobilization of extra- and intracellular Ca. POH (1000 μM) inhibited contractions induced by BaCl (0.1-30 mM) in a similar way to nifedipine (10 μM), indicating a possible blockade of L-type VOCC. In the presence of potassium channel blockers, tetraethylammonium (1 mM), 4-aminopyridine (1 mM), or glibenclamide (10 μM), an increase in the EC value of the POH was observed, suggesting a modulation of the activity of BK, K, and K channels.

Conclusion: The data from this study suggest that POH modulates Ca and K ion channels to induce a relaxant response in HUA.

Citing Articles

Exposure to DEP Modifies the Human Umbilical Artery Vascular Resistance Contributing to Hypertension in Pregnancy.

Mariana M, Soares A, Castelo-Branco M, Cairrao E J Xenobiot. 2024; 14(2):497-515.

PMID: 38651380 PMC: 11036297. DOI: 10.3390/jox14020030.

References

Bhatia S, McGinty D, Letizia C, Api A . Fragrance material review on carveol. Food Chem Toxicol. 2008; 46 Suppl 11:S85-7. DOI: 10.1016/j.fct.2008.06.032. View

Garcia D, Amorim L, de Castro Faria M, Freire A, Santelli R, da Fonseca C . The anticancer drug perillyl alcohol is a Na/K-ATPase inhibitor. Mol Cell Biochem. 2010; 345(1-2):29-34. DOI: 10.1007/s11010-010-0556-9. View

Gomes A, Mello A, Ribeiro M, Garcia D, da Fonseca C, Salazar M . Perillyl alcohol, a pleiotropic natural compound suitable for brain tumor therapy, targets free radicals. Arch Immunol Ther Exp (Warsz). 2017; 65(4):285-297. DOI: 10.1007/s00005-017-0459-5. View

Bejeshk M, Beik A, Aminizadeh A, Salimi F, Bagheri F, Sahebazzamani M . Perillyl alcohol (PA) mitigates inflammatory, oxidative, and histopathological consequences of allergic asthma in rats. Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(6):1235-1245. DOI: 10.1007/s00210-023-02398-5. View

Quaiyoom Khan A, Nafees S, Sultana S . Perillyl alcohol protects against ethanol induced acute liver injury in Wistar rats by inhibiting oxidative stress, NFκ-B activation and proinflammatory cytokine production. Toxicology. 2010; 279(1-3):108-14. DOI: 10.1016/j.tox.2010.09.017. View

Sousa M, Afonso A, Teixeira L, Borges A, Saavedra M, Simoes L . Hydrocinnamic Acid and Perillyl Alcohol Potentiate the Action of Antibiotics against . Antibiotics (Basel). 2023; 12(2). PMC: 9952493. DOI: 10.3390/antibiotics12020360. View

Ripple G, Gould M, Stewart J, Tutsch K, Arzoomanian R, Alberti D . Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res. 1998; 4(5):1159-64. View

Hudes G, Szarka C, Adams A, Ranganathan S, McCauley R, Weiner L . Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res. 2000; 6(8):3071-80. View

Ripple G, Gould M, Arzoomanian R, Alberti D, Feierabend C, Simon K . Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res. 2000; 6(2):390-6. View

10.

Azzoli C, Miller V, Ng K, Krug L, Spriggs D, Tong W . A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2003; 51(6):493-8. DOI: 10.1007/s00280-003-0599-7. View

11.

Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R . Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol. 2003; 52(5):361-6. DOI: 10.1007/s00280-003-0684-y. View

12.

Bailey H, Wilding G, Tutsch K, Arzoomanian R, Alberti D, Feierabend C . A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother Pharmacol. 2004; 54(4):368-76. DOI: 10.1007/s00280-004-0788-z. View

13.

Schonthal A, Peereboom D, Wagle N, Lai R, Mathew A, Hurth K . Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neurooncol Adv. 2021; 3(1):vdab005. PMC: 7879254. DOI: 10.1093/noajnl/vdab005. View

14.

Bailey H, Levy D, Harris L, Schink J, Foss F, Beatty P . A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol Oncol. 2002; 85(3):464-8. DOI: 10.1006/gyno.2002.6647. View

15.

Meadows S, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D . Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest Cancer. 2003; 32(2-3):125-8. DOI: 10.1385/IJGC:32:2-3:125. View

16.

Liu G, Oettel K, Bailey H, van Ummersen L, Tutsch K, Staab M . Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs. 2003; 21(3):367-72. DOI: 10.1023/a:1025437115182. View

17.

Bailey H, Attia S, Love R, Fass T, Chappell R, Tutsch K . Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol. 2007; 62(1):149-57. DOI: 10.1007/s00280-007-0585-6. View

18.

da Fonseca C, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T . Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol. 2008; 70(3):259-66. DOI: 10.1016/j.surneu.2007.07.040. View

19.

Kennedy S, Wadsworth R, Wainwright C . Effect of antiproliferative agents on vascular function in normal and in vitro balloon-injured porcine coronary arteries. Eur J Pharmacol. 2003; 481(1):101-7. DOI: 10.1016/j.ejphar.2003.09.010. View

20.

Cardoso-Teixeira A, Ferreira-da-Silva F, Peixoto-Neves D, Oliveira-Abreu K, Pereira-Goncalves A, Coelho-de-Souza A . Hydroxyl Group and Vasorelaxant Effects of Perillyl Alcohol, Carveol, Limonene on Aorta Smooth Muscle of Rats. Molecules. 2018; 23(6). PMC: 6099955. DOI: 10.3390/molecules23061430. View